TIRV HA

**TIRV HA** is a reported investigational trivalent modified messenger RNA influenza vaccine candidate. It is described as a lipid nanoparticle-formulated nucleoside-modified mRNA vaccine encoding full-length influenza hemagglutinin antigens, intended to induce protective humoral and cellular immunity against seasonal influenza A and influenza B viruses. Public sources verify related Pfizer and BioNTech trivalent influenza mRNA vaccine programs and an hVIVO-sponsored influenza A/H1N1 modRNA human-challenge study, but they do not clearly verify the exact designation \"TIRV HA\" or establish it as a distinct named clinical asset.

Other names

Trivalent Influenza RNA Vaccine Hemagglutinin Antigen